Evotec beschleunigt Zugang zu biologischen Therapeutika mit Bau einer Produktionsanlage in Toulouse bionity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bionity.com Daily Mail and Mail on Sunday newspapers.
Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
DGAP-News: Evotec SE / Key word(s): Miscellaneous
20.04.2021 / 07:30
J.POD
(R) 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19
EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE
CONSTRUCTION OF THE J.POD
Hamburg, Germany, 20 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD
(R) 2 EU biologics manufacturing facility at Evotec s Campus Curie in Toulouse, France. J.POD
Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evotec AG: Evotec And Exscientia Announce Start of Human Clinical Trials of Novel Immuno-Oncology Drug
EXSCIENTIA TO LEAD CLINICAL DEVELOPMENT PHASE
EVOTEC RETAINS CO-OWNERSHIP RIGHTS DURING CLINICAL DEVELOPMENT
HAMBURG, GERMANY / ACCESSWIRE / April 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia s next generation 3-D evolutionary AI-design platform, Centaur Chemist
(R). The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-me